With the March 2 completion of the multi-billion-dollar asset swaps between GlaxoSmithKline PLC and Novartis AG, it’s now down to execution to see which company can play a better hand with products originally marketed by the other. The results are likely more critical for troubled GSK than the more buoyant Novartis.
GlaxoSmithKline and its high-profile CEO Andrew Witty have had a torrid past 12 months. The company was fined $485 million for bribery in China in September 2014 ([A#14140922004]). And...